全文获取类型
收费全文 | 8490篇 |
免费 | 487篇 |
国内免费 | 156篇 |
专业分类
耳鼻咽喉 | 299篇 |
儿科学 | 285篇 |
妇产科学 | 666篇 |
基础医学 | 961篇 |
口腔科学 | 212篇 |
临床医学 | 542篇 |
内科学 | 598篇 |
皮肤病学 | 573篇 |
神经病学 | 420篇 |
特种医学 | 187篇 |
外科学 | 952篇 |
综合类 | 1156篇 |
现状与发展 | 1篇 |
一般理论 | 1篇 |
预防医学 | 523篇 |
眼科学 | 345篇 |
药学 | 617篇 |
4篇 | |
中国医学 | 364篇 |
肿瘤学 | 427篇 |
出版年
2023年 | 103篇 |
2022年 | 189篇 |
2021年 | 318篇 |
2020年 | 301篇 |
2019年 | 257篇 |
2018年 | 274篇 |
2017年 | 285篇 |
2016年 | 292篇 |
2015年 | 239篇 |
2014年 | 603篇 |
2013年 | 597篇 |
2012年 | 515篇 |
2011年 | 575篇 |
2010年 | 417篇 |
2009年 | 390篇 |
2008年 | 384篇 |
2007年 | 370篇 |
2006年 | 401篇 |
2005年 | 283篇 |
2004年 | 248篇 |
2003年 | 245篇 |
2002年 | 200篇 |
2001年 | 184篇 |
2000年 | 149篇 |
1999年 | 138篇 |
1998年 | 91篇 |
1997年 | 90篇 |
1996年 | 86篇 |
1995年 | 95篇 |
1994年 | 79篇 |
1993年 | 65篇 |
1992年 | 86篇 |
1991年 | 55篇 |
1990年 | 49篇 |
1989年 | 54篇 |
1988年 | 38篇 |
1987年 | 43篇 |
1986年 | 31篇 |
1985年 | 79篇 |
1984年 | 46篇 |
1983年 | 34篇 |
1982年 | 37篇 |
1981年 | 31篇 |
1980年 | 12篇 |
1979年 | 11篇 |
1978年 | 11篇 |
1977年 | 7篇 |
1976年 | 22篇 |
1973年 | 6篇 |
1971年 | 4篇 |
排序方式: 共有9133条查询结果,搜索用时 31 毫秒
1.
《Revista brasileira de otorrinolaringologia (English ed.)》2022,88(4):621-624
ObjectivesRecurrent Aphthous Stomatitis (RAS) a chronic idiopathic oral mucosal disease. But yet the etiology and pathogenesis of RAS are not exactly known, it is thought that inflammation play an important role in the pathogenesis. The aim of this study is to demonstrate the role of systemic inflammation among the possible etiological factors of RAS and to find the possible diagnostic correlation between Systemic Immune Inflammation Index (SII).MethodsPatients who were consulted the otolaryngology outpatient clinic and diagnosed with RAS between 2019–2021 were retrospectively analyzed. Neutrophil/Lymphocyte Ratio (NLR), Platelet/Lymphocyte Ratio (PLR) and SII values were calculated based on the results of complete blood count. Demographic and hematological parameters between control and RAS groups were compared. The statistical significance level was considered as <0.05.ResultsThere was no statistically significant difference between the control and RAS groups in terms of sex and age distributions (p = 0.566 and p = 0.173, respectively). SII, NLR and PLR values were significantly higher in the RAS group compared to the controls (p < 0.001, p < 0.001 and p = 0.001, respectively). A very strong correlation between SII and NLR, moderately strong correlation between SII and PLR and moderate correlation between NLR and PLR values were detected (respectively ρ: 0.813, 0.719, 0.532; p-values <0.001).ConclusionSII, NLR and PLR has significantly higher levels in the RAS group compared to the control group, that it supports the role of systemic inflammation in the etiopathogenesis of RAS. In addition, the results show that SII is a valuable marker for inflammation.Level of evidence4. 相似文献
2.
3.
Raazia Tasadduq Laiba Ajmal Farhat Batool Tehniyat Zafar Aleena Babar Amna Riasat Abdul-Rauf Shakoori 《Human immunology》2021,82(3):162-169
Maintenance and progression of pregnancy is an intricate process governed by a variety of developmental cues. Recurrent pregnancy loss (RPL) is a complication experienced by expecting mothers that is defined as three or more consecutive pregnancy losses. This review focuses on the dysfunctions of the immune system as one of the key contributors towards RPL. The current data suggests that the alloimmune and autoimmune factors contribute to the loss of fetus. Such causes despite being recognized as a definitive reason for recurrent pregnancy loss, are still under extensive investigation with new parameters being discovered and scrutinized for their association with RPLs. More in-depth and high throughput studies are required for devising better diagnostic tools and management strategies for the affected female so that they can carry their pregnancy to term. 相似文献
4.
《Vaccine》2021,39(40):5729-5731
IntroductionConcerns were raised over an increase in Bell's palsy, herpes simplex and herpes zoster after BNT162b2 vaccination, all are manifestations of herpesviruses reactivation. As herpesviruses commonly reactivate in the oropharynx, we have hypothesized that oropharyngeal shedding of herpesviruses will increase after vaccination.MethodsImmune-competent Adults, excluding those using topical steroids or manifesting symptomatic herpesvirus infection, were sampled before BNT162b2 vaccination and one week after. Herpesviruses 1–7 shedding was tested with a multiplexed PCR.ResultsIn 103 paired samples the prevalence of herpesviruses was similar before and after vaccination: HSV1, 3.9% vs. 5.8% (p = 0.75); HSV2, 0% vs. 1% (p = not applicable, NA); VZV, 0% vs. 0% (p = NA); EBV, 14.6% vs. 17.5% (p = 0.63); CMV, 0% vs. 0% (p = NA); HHV6, 4.9% vs. 7.8% (p = 0.55); HHV7, 71.8% vs. 72.8% (p = 1); any herpesvirus, 73.8% vs. 74.8% (p = 1).DiscussionWe did not find evidence for increased oropharyngeal reactivation of herpesviruses one week after BNT162b2. 相似文献
5.
目的探讨细胞色素P450药物代谢酶(CYP)2C19基因分型与氯吡格雷治疗的急性缺血性脑卒中患者再发脑卒中的关系。方法选取2018年5月—2018年12月常州市第一人民医院收治接受氯吡格雷治疗的159例急性缺血性脑卒中患者,检测患者入院后空腹外周血中CYP2C19*2,CYP2C19*3基因分型。对患者进行随访,随访截至2020年2月,观察再发脑卒中的情况,并分析CYP2C19*2,CYP2C19*3基因分型与再发脑卒中关系。结果随访时间14~22个月,平均随访时间为(18.2±1.5)个月,共7例患者失访,共20例(13.2%)患者复发缺血性脑卒中。再发脑卒中患者中CYP2C19*2 GG型及CYP2C19*3 GG型均低于无复发患者(P<0.05),CYP2C19*2 GA型,CYP2C19*2 AA型CYP2C19*3 GA型,CYP2C19*3AA型均高于无复发患者(P<0.05)。Kaplan-Meier法并Log-rank检验结果显示,CYP2C19*2 GG型无复发时间长于AA型,差异有统计学意义(Log-rank=6.759,P=0.034)。CYP2C19*3GG型无复发时间长于AA型,差异有统计学意义(Log-rank x2=8.660,P=0.013)。多因素Cox分析结果显示,糖尿病、氯吡格雷抵抗,CYP2C19*2及CYP2C19*3基因型是再发脑卒中影响因素(P<0.05)。结论在接受氯吡格雷治疗急性缺血性脑卒中患者中,CYP2C19*2及CYP2C19*3突变型再发脑卒中的风险明显增高。 相似文献
6.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献7.
《Vaccine》2019,37(50):7408-7418
The development of vaccines against herpes simplex virus (HSV) is an important global goal for sexual and reproductive health. A key priority to advance development of HSV vaccines is the definition of preferred product characteristics (PPCs), which provide strategic guidance on World Health Organization (WHO) preferences for new vaccines, specifically from a low- and middle-income country (LMIC) perspective. To start the PPC process for HSV vaccines, the WHO convened a global stakeholder consultation in March 2017, to define the priority public health needs that should be addressed by HSV vaccines and discuss the key considerations for HSV vaccine PPCs, particularly for LMICs. Meeting participants outlined an initial set of overarching public health goals for HSV vaccines in LMICs, which are: to reduce the acquisition of HIV associated with HSV-2 infection in high HIV-prevalence populations and to reduce the burden of HSV-associated disease, including mortality and morbidity due to neonatal herpes and impacts on sexual and reproductive health. Participants also considered the role of prophylactic versus therapeutic vaccines, whether both HSV-2 and HSV-1 should be targeted, important target populations, and infection and disease endpoints for clinical trials. This article summarizes the main discussions from the consultation. 相似文献
8.
9.
背景 复发性流产(RSA)发病率呈逐年上升趋势,严重影响妇女身心健康,目前现代医学对RSA的病因和发病机制尚未完全明确。目的 了解RSA病因的分布情况,以及流产孕周与流产次数和RSA病因之间的关系。方法 选取2018年在新疆医科大学第二附属医院确诊为RSA的患者198例,收集患者的一般资料包括年龄、自然流产次数、流产孕周,并筛查患者的病因:染色体异常、生殖道解剖结构异常、内分泌系统异常、生殖道感染、自身免疫异常等,并对这些资料进行回顾性分析。根据患者的流产孕周,分为早期RSA组(<12周)(155例)和晚期RSA组(≥12周)(43例);根据流产次数分为2次组(123例)和≥3次组(75例)。分析RSA患者各病因所占比例,以及RSA病因在不同流产孕周组和不同流产次数组间的差异。结果 198例RSA患者,染色体异常9例(4.55%),生殖道解剖结构异常11例(5.56%),内分泌系统异常36例(18.18%),生殖道感染14例(7.07%),自身免疫异常30例(15.15%),不明病因98例(49.49%)。晚期RSA组患者生殖道解剖结构异常发生率大于早期RSA组,不明病因发生率低于早期RSA组(P<0.05);早期RSA组与晚期RSA组患者染色体异常、内分泌系统异常、生殖道感染、自身免疫异常发生率比较,差异均无统计学意义(P>0.05)。流产次数2次组和流产次数≥3次组患者染色体异常、生殖道解剖结构异常、内分泌系统异常、生殖道感染、自身免疫异常、不明病因发生率比较,差异均无统计学意义(P>0.05)。结论 导致RSA的病因有多种,包括染色体异常、生殖道解剖结构异常、内分泌系统异常、生殖道感染、自身免疫异常及不明病因等多种因素,其中不明病因的RSA占多数;生殖道解剖结构异常对妊娠晚期的影响大于妊娠早期。 相似文献
10.
Chi-Chih Wang Ming-Hseng Tseng Sheng-Wen Wu Tzu-Wei Yang Hsuan-Yi Chen Wen-Wei Sung Chang-Cheng Su Yao-Tung Wang Chun-Che Lin Ming-Chang Tsai 《World journal of gastrointestinal oncology》2020,12(12):1381-1393
BACKGROUNDCholangiocarcinoma is a disease with a high mortality rate. Our previous study revealed that cholelithiasis patients who undergo endoscopic sphincterotomy (ES)/endoscopic papillary balloon dilatation are at a higher risk for subsequent cholangiocarcinoma than cholelithiasis patients who undergo cholecystectomy.AIMTo clarify the relationship between recurrent biliary events and subsequent cholangiocarcinoma risk in choledocholithiasis patients.METHODSFrom one million random cases in the Taiwan National Health Insurance Research Database 2004–2011, we selected symptomatic choledocholithiasis patients older than 18 years who were admitted from January 2005 to December 2009 (study group). Cases for a control group were defined as individuals who had never been diagnosed with cholelithiasis, matched by sex and age in a 1:3 ratio. The study group was further divided into ES/endoscopic papillary balloon dilatation, both ES/endoscopic papillary balloon dilatation and cholecystectomy, and no intervention groups.RESULTSWe included 2096 choledocholithiasis patients without previous intervention or cholangiocarcinoma. A total of 12 (2.35%), 11 (0.74%), and 1 (1.00%) subsequent cholangiocarcinoma cases were diagnosed among 511 ES/endoscopic papillary balloon dilatation patients, 1485 patients with no intervention, and 100 ES/endoscopic papillary balloon dilatation and cholecystectomy patients, respectively. The incidence rates of recurrent biliary event were 527.79/1000 person-years and 286.69/1000 person-years in the subsequent cholangiocarcinoma and no cholangiocarcinoma group, showing a high correlation between subsequent cholangiocarcinoma risk and recurrent biliary events.CONCLUSIONCholedocholithiasis patients who undergo further cholecystectomy after ES/endoscopic papillary balloon dilatation have decreased subsequent cholangiocarcinoma risk due to reduced recurrent biliary events. 相似文献